Articles tagged with Insulin
A new AI algorithm enabled a fully automated artificial pancreas system to achieve improved glucose control without manual input of meal or exercise information. This breakthrough could lead to more efficient and hassle-free diabetes management.
Researchers found that an experimental treatment converted cells to generate insulin, reducing diabetic symptoms and increasing insulin cell mass. The treatment showed promise for regenerating insulin-producing capacity and restoring normal blood glucose balance.
CU Anschutz researchers found a correlation between inflammatory T-cell responses to hybrid insulin peptides and worsening blood glucose measurements in genetically at-risk adolescents. This study provides an important advancement in identifying the risk of T1D early and potential for intervention.
A study by MSF and UNIGE found that insulin can be stored at temperatures ranging from 25°C to 37°C for four weeks without losing its potency or efficacy. This breakthrough allows people with diabetes to manage their condition independently, reducing the need for daily hospital visits.
A team of researchers found that immature beta-cells can contribute to proper insulin release when paired with more mature counterparts. By balancing the proportion of 'weak' and 'strong' beta-cells, islet function can be restored under conditions of metabolic stress.
Researchers have discovered a novel and druggable insulin inhibitory receptor named inceptor. Blocking its function leads to increased sensitisation of the insulin signalling pathway in pancreatic beta cells, allowing for potential protection and regeneration of beta cells for diabetes remission.
A study analyzing 4,000 social media posts found that diabetics in the UK fear disrupted insulin supplies as a result of Brexit. The research highlights the financial burden of accessing insulin and the need for improved healthcare systems.
The International Diabetes Closed-Loop (iDCL) Trial found that hybrid closed-loop insulin therapy significantly improved glycemic control in patients with type 1 diabetes. The use of this technology increased Time in Range by 13%, especially during nighttime hours, and reduced time spent at blood glucose levels above 180 mg/dL.
A Brazilian study found that children born to obese mothers are more prone to developing metabolic disease due to a lack of the Mfn2 protein in their mother's eggs. This protein regulates mitochondrial function and energy production, leading to abnormal mitochondria shape and dysfunction.
A small, highly controlled study at the National Institutes of Health compared the effects of a low-fat, plant-based diet to a low-carb, animal-based diet on calorie intake, hormone levels, body weight, and more. Participants lost weight on both diets, but only the low-fat diet led to a significant loss of body fat.
The American Diabetes Association has lowered the target HbA1C levels for children with type-1 diabetes to less than 7% to reduce acute and long-term organ damage. The new guidelines aim to improve immediate and long-term health outcomes, fewer complications, and reduced mortality rates in T1D children.
The Endocrine Society recommends government negotiation, greater transparency, and policy changes to reduce insulin costs. These policies aim to increase access to affordable insulin, particularly for low-income individuals and Medicare beneficiaries.
Researchers at NTU Singapore have developed oral insulin nanoparticles that can carry large amounts of insulin, making them a potential alternative to painful injections. The nanoparticles are stable and able to pass through the intestinal wall into the bloodstream, offering a promising solution for diabetic patients.
Scientists have developed advanced imaging techniques to observe pancreatic beta cells packaging insulin and responding to drug treatments. The new methods provide a more complete picture of the cell's functions and components, shedding light on the mechanisms responsible for preventing diabetes.
A new study from the University of Eastern Finland found that consuming blackcurrants after a meal can attenuate the rise and fall of blood glucose levels. The beneficial effect is attributed to berry-derived polyphenolic compounds, specifically anthocyanins, which slow down glucose absorption and reduce oxidative stress.
Researchers from the University of Copenhagen have developed a new insulin molecule that can sense blood sugar levels and release insulin accordingly. This innovative approach aims to reduce the frequency of injections and monitoring required by people with type 1 diabetes, improving their quality of life.
A standardized 'Artificial Pancreas (AP) Dashboard' is proposed to improve glycemic control and reduce hypoglycemia in insulin requiring patients with diabetes. The dashboard provides a single-page report of seven main components, including glucose metrics, insulin management, and user experience.
Researchers discovered a previously unknown way that pancreatic cells decide how much insulin to secrete, pointing to an overlooked enzyme known as pyruvate kinase. Stimulating pyruvate kinase not only increases the secretion of insulin but also has other metabolically protective effects in the liver, muscle and red blood cells.
A study using genome sequencing and CRISPR gene editing tools has uncovered a new biological pathway essential for insulin production in the YIPF5 gene. The research shows that genetic changes in this gene result in high stress levels, leading to cell death in insulin-producing cells.
A recent study suggests that the evolution of insulin has encountered a roadblock, rendering most people vulnerable to Type 2 diabetes. The researchers discovered that even slight variations in the insulin-sequencing process can impair insulin folding and induce cellular stress.
A new study has shown that a minimally-invasive ablation procedure can rejuvenate the lining of the duodenum, leading to significant improvements in blood glucose control and weight loss. In a pilot study, 75% of patients with type 2 diabetes who underwent the procedure were able to discontinue insulin therapy within six months.
A new study by the RAND Corporation found that US insulin prices are significantly higher than those in other high-income countries, even when accounting for rebates and discounts. The average price per unit across all types of insulin in the US is $98.70, compared to a fraction of this cost in other nations.
Researchers at Pennington Biomedical Research Center will investigate how the SGK1 enzyme regulates beta-cell mass when more insulin is needed. The study aims to understand how beta-cell growth mechanisms influence insulin release, potentially leading to new medications for diagnosing and treating metabolic diseases.
A 15-year study found that non-Hispanic white children are more likely to use insulin pumps than non-Hispanic Black children, exacerbating racial disparities in type 1 diabetes outcomes. Researchers emphasize the need for interventions to address these disparities and promote equitable care.
A new study reveals that reversing type 2 diabetes can restore the pancreas to a normal size and shape, improving insulin function. After 2 years of weight loss, responders experienced significant growth in pancreas volume and fat reduction, while non-responders showed no change.
A new study confirms the existence of residual, non-functioning beta cells in living individuals with longstanding type 1 diabetes. Researchers used a non-invasive imaging technique to detect these cells, which may be restored if adequate treatments are available.
A study found that a ferry protein in the pancreas plays a crucial role in regulating insulin levels and protecting against the negative effects of a high-fat diet. The researchers discovered that this protein, VMAT2, helps to shield beta cells from oxidative stress, which can lead to diabetes.
The study found that youth using the artificial pancreas system had significant improvements in blood glucose control, including a 7% improvement during the daytime and a 26% improvement at night. The technology improved overall time-in-range by nearly 11%, translating to more hours per day in a healthy range.
A clinical trial found that a new artificial pancreas system improved blood glucose control in children aged 6-13, achieving 7% daytime improvement and 26% nighttime control. The technology replaces traditional testing and insulin delivery, providing greater convenience and safety.
A genetic variant of the DUSP8 gene impairs brain response to insulin, leading to increased risk of type 2 diabetes. Research reveals protein Dusp8's regulatory effects on hypothalamic insulin sensitivity and inflammatory processes.
Salk Institute scientists develop transplantable human insulin-producing pancreatic cell clusters that evade the immune system, providing sustained blood glucose control without immunosuppressants. The cells were created using stem cell technology and a protein called WNT4 to induce a genetic switch that makes them functional.
Researchers develop a new mouse model of permanent neonatal diabetes using the Kuma mutation, which exhibits severe insulin-deficiency and beta-cell dysfunction in an immune deficient background. The study successfully reverses hyperglycemia with insulin implants, making it suitable for islet transplantation research.
A national cost-sharing cap on insulin can help reduce the financial burden on families of children and young adults with type 1 diabetes. The study found that approximately 60% of patients would benefit from a $25 cap, with average savings of almost $480 per year.
Case studies published by Physicians Committee for Responsible Medicine found that plant-based diets rich in whole carbohydrates improved health markers in individuals with type 1 diabetes. The diets led to decreased insulin needs, stabilized blood sugar control, and reduced cholesterol levels.
A study in Journal of Biological Chemistry describes a new way to determine the age of insulin-storage parcels and sheds light on how their age affects their release into the bloodstream. This finding could help experts better understand diabetes and fine-tune therapies for it.
Stanford researchers developed a new ultrafast insulin formulation that stabilizes monomeric insulin for over 24 hours, allowing it to take effect almost immediately upon injection. The formulation could potentially reduce the time it takes for insulin to reach peak activity by four-fold.
A new ultra-rapid insulin formulation, UFAL, reached peak activity in pigs with diabetes twice as fast as Humalog, a commercially available option. This could lead to faster quality-of-life improvements for diabetic patients by allowing quicker blood sugar level management during mealtimes.
Diabetic ketoacidosis is a common and severe complication in hospitalized patients with COVID-19, causing dehydration and breathing difficulties. A new clinical perspective outlines simpler methods of management to protect healthcare providers and keep ICU beds available for severe cases.
A Phase 2 study led by UB pediatric endocrinologist Teresa Quattrin shows that golimumab, an anti-TNF therapy, preserved beta-cell function and reduced injected insulin required in children and young adults with newly diagnosed Type 1 diabetes. The study demonstrated a higher C-peptide level in patients treated with golimumab compared ...
Researchers at Oregon Health & Science University have developed an AI algorithm that uses data from continuous glucose monitors and wireless insulin pens to provide guidance on adjustments. The algorithm, paired with a smartphone app called DailyDose, generated recommendations in agreement with physicians 67.9% of the time.
The study shows that the FreeStyle Libre 14 day system is estimated to save roughly 50% in average costs associated with severe hypoglycemia for people with type 1 and type 2 diabetes. Annual cost savings are 61% and 63% lower compared to traditional fingerstick testing.
A new study finds that people with Type 1 diabetes spend an average of $2,500 a year on healthcare costs, with diabetes-related supplies costing more than insulin. The study also highlights the importance of automating glucose monitoring and insulin delivery for young children and adolescents with Type 1 diabetes.
Researchers created a mini-insulin molecule that combines human insulin's potency with the fast-acting potential of cone snail venom, potentially improving blood sugar control. The hybrid insulin has the same potency as human insulin but acts faster, making it a prime candidate for new diabetes treatments.
Researchers have developed a wearable device that uses external electric fields to trigger insulin release from bioengineered cells, stabilizing blood glucose levels in mice. The approach opens the door for remote-controlled diabetes therapies and represents an expansion of electrogenetic toolboxes for human therapeutics.
Researchers at ETH Zurich create implant that uses electrical signals to stimulate insulin production in diabetic mice, offering potential breakthrough for real-time glycemic control. The system is designed to be connected to the internet and controlled via an app, paving the way for a more integrated approach to diabetes management.
A study revealed that insufficient insulin action in adipocytes leads to the development of diabetes and NASH by hyperactivating the protein FoxO1. This finding could serve as a potential target for new drug development for these conditions.
Researchers at Stanford University have developed a way to combine insulin with amylin, a second hormone that plays a synergistic role in controlling blood sugar levels. The new technique involves a protective coating that allows the two hormones to coexist in a single shot, enabling patients to take a double-acting injection.
Researchers developed a novel approach to decontaminate single-cell RNA seq data, allowing for accurate quantification of cell-specific drug effects in pancreatic islets. The method revealed species-specific and cell-type-specific responses to drugs, including the induction of insulin production in alpha cells.
A study funded by JDRF, ADA, and Helmsley found all human and analog insulins in US pharmacies contained the expected amount of active insulin, posing no safety risks for people with diabetes.
Researchers found that patients with type 2 diabetes have blood vessels resistant to insulin, leading to elevated oxidative stress and vessel dysfunction. A new therapy combining insulin treatment with DPP4 inhibitors shows promise in reversing damaging vascular effects.
Two case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in adults and infants during the pandemic. The technology showed improved outcomes with increased time-in-range, as patients received virtual management and dose adjustments.
Type 2 diabetes patients exhibit elevated glucagon levels due to α-cell resistance to insulin. Glucagon counteracts insulin's effects, exacerbating high blood sugar levels.
A recent study found that technology use by adults with type 1 diabetes is lower among African-American and Hispanic patients. The use of continuous glucose monitors (CGM) and continuous subcutaneous insulin infusion (CSII) devices was significantly lower in these groups, highlighting racial disparities in access to healthcare.
A new study finds that a wearable device called V-Go can safely deliver regular human insulin (RHI) to patients with type 2 diabetes, achieving good blood sugar control. The study, which compared RHI to rapid acting insulin (RAI) analogs, showed improvements in hemoglobin A1c levels and met its primary endpoint of noninferiority.
A team of international medical experts successfully delivered insulin via a drone to a patient living in a remote community in Ireland, addressing healthcare access issues. The project demonstrated the potential for autonomous drones to deliver life-saving medications and supplies in disaster scenarios.
A study analyzing 6 million days of real-world data shows the MiniMed 670G system can maintain target glucose range of 70-180 mg/dL over 71% of the time. The AutoMode feature improves glycemic control, reducing low and high blood sugar episodes.
Researchers at MIT have developed a way to encapsulate therapeutic cells in a flexible protective device that prevents immune rejection while allowing oxygen and nutrients to reach the cells. This technology could lead to long-term treatment of chronic diseases such as diabetes.
Researchers at UW-Madison discovered that removing a specific gene from insulin-producing cells can prevent Type 1 diabetes in mice by allowing the cells to disguise themselves from immune cells. This genetic manipulation enabled the cells to evade an autoimmune response, leading to normal glucose levels and insulin production.
Research reveals that children diagnosed with type 1 diabetes under 7 years old have a different form of the condition compared to those diagnosed at 13 or above. The study proposes two distinct endotypes: T1DE1 and T1DE2, which could lead to new treatments and a potential cure for some people.
Researchers developed a mathematical model to predict the behavior of glucose-responsive insulins in humans and rodents. The model identified optimal designs that could work well in both species, with about 13% predicted to be effective in both, and 14% in humans alone.